Kahn Swick & Foti, LLC has notified investors in Erasca, Inc. of an August 10, 2026 deadline to apply for lead plaintiff status in a pending securities class action lawsuit. The suit, filed in the United States District Court for the Southern District of California, seeks to recover losses for shareholders who purchased Erasca shares between January 14, 2025 and April 26, 2026. The complaint alleges that the company and certain executives failed to disclose that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc., exposing Erasca to patent and trade secret violation risks, and that defendants lacked a reasonable basis for their positive statements about the drug candidate. Investors who suffered losses during the class period may contact KSF Managing Partner Lewis Kahn to learn more, and they do not need to serve as lead plaintiff to share in any potential recovery.
Erasca IncSecurities class action lawsuit alleging failure to disclose improper comparisons and patent/trade secret risks for ERAS-0015.
Revolution Medicines Inc